Baxter International BAX Drug Compounding — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Baxter International in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Baxter International’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Baxter International's drug compounding — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Baxter International's drug compounding — net sales?
- Baxter International (BAX) reported drug compounding — net sales of $320M in Q1 2026.
- How has Baxter International's drug compounding — net sales changed year-over-year?
- Baxter International's drug compounding — net sales increased by 30.1% year-over-year, from $246M to $320M.
- What is the long-term trend for Baxter International's drug compounding — net sales?
- Over 3 years (2021 to 2025), Baxter International's drug compounding — net sales has grown at a 8.2% compound annual growth rate (CAGR), from $901M to $1.14B.
- What does drug compounding — net sales mean?
- The total revenue earned from providing customized, patient-specific pharmaceutical medications.
- How do you interpret drug compounding — net sales?
- An increase suggests strong demand for outsourced pharmacy services and successful scaling of production capabilities, while a decrease may indicate regulatory challenges, supply chain disruptions, or increased competition in the compounding market.
- How does drug compounding — net sales compare across companies?
- Peers in the medical supply and pharmacy services industry typically report this as a specialized revenue stream within their broader pharmaceutical or hospital services segments, often benchmarked against overall hospital pharmacy outsourcing trends.